TMDX
TransMedics Group, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 24 ▲ TransMedics reported strong fourth quarter and full year 2025 financ…
- Mar 2 to Mar 4 ▼ 2 days of insider sells: $823.0K by 3 insiders, avg $146.23
- Jun 12 ▲ TransMedics attracted heavy net institutional accumulation in Q3 202…
- Jun 15 ▼ 1 insider sell $722.4K at $75.06
- Jul 28 UBS initiates
- Sep 11 ▲ 1 insider buy $109.1K at $81.63
- Oct 7 Barclays initiates
- Nov 5 ▲ Earnings: TMDX Q3 2026 Earnings: EPS $0.51 (+71.3% vs est)
- Nov 5 ▲ TransMedics reported Q3 2026 revenue of $203.0M (+41% YoY) and GAAP…
- Nov 9 ▼ 1 insider sell $385.5K at $94.97
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $109.1K at an average $81.63. 5 insiders sold $1.9M. Price is 13% above their cost.
- InstitutionsMIXED
Q3 2026: 20 added (2 new), 25 trimmed or exited. Largest new: Barrow Hanley Mewhinney & Strauss $69.9M.
- AnalystsBULLISH
14 of 19 rate it Buy or better. Median target $110.00 (+19%).
- EstimatesFALLING
Current-quarter EPS estimate $0.530 → $0.451 over 90 days. 2 up, 6 down in 30 days.
- Short sellersSTEADY
Short interest +1.2% to 8.88M shares. 10.2 days to cover, ≈25.6% of shares.
- TrendUPTREND
15% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 6.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BARROW HANLEY MEWHINNEY & STRAUSS LLC | NEW | $69.9M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $34.3M |
| PRINCIPAL FINANCIAL GROUP INC | ADD | $31.1M |
| BARCLAYS PLC | ADD | $27.8M |
| HRT FINANCIAL LP | ADD | $24.2M |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | ADD | $12.3M |
| CITIGROUP INC | TRIM | $8.6M |
| Invesco Ltd. | NEAR_EXIT | $7.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analystsPrice is inside the target range. Median implies +19%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | UBS MAINTAIN | Neutral |
| Nov 6, 2026 | JP Morgan MAINTAIN | Neutral |
| Nov 6, 2026 | Needham MAINTAIN | Buy |
| Nov 6, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Oct 13, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Oct 7, 2026 | Barclays INITIATE | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
TOBIN JAMES R Director Nov 9, 2026 | SELL | $5.5K |
TOBIN JAMES R Director Nov 9, 2026 | SELL | $379.9K |
Araujo Fernando N. See Remarks Oct 28, 2026 | AWARD | 34,419 sh |
Araujo Fernando N. See Remarks Oct 28, 2026 | AWARD | 22,969 sh |
Weill David Director Sep 11, 2026 | BUY | $109.1K |
TOBIN JAMES R Director Aug 17, 2026 | GIFT | 18,000 sh |
Corcoran Nicholas See remarks Jul 10, 2026 | AWARD | 11,727 sh |
Hernandez Gerardo Chief Financial Officer Jul 10, 2026 | AWARD | 17,246 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.45 | $0.34–$0.53 | -9.7% | $202.8M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 5 bullish · 0 bearish · 4 neutral- NEUTRAL 144Nov 9, 2026
Director James R. Tobin filed a Form 144 notice of intent to sell 4,059 shares of TransMedics…
The proposed sale is small relative to market cap and appears to be a routine diversification move by a director. Monitor whether the sale actually executes and if other insiders follow with similar…
- BULLISH 8-KNov 5, 2026
TransMedics reported Q3 2026 revenue of $203.0M (+41% YoY) and GAAP EPS of $0.46, beating…
The strong Q3 beat and raised guidance signal accelerating momentum in the core NOP business ahead of ENHANCE Heart Part B and DENOVO Lung catalysts. Monitor the Q4 call for initial enrollment…
- BULLISH PRESS-RELEASENov 5, 2026
TransMedics reported Q3 2026 revenue of $203.0M (+41% YoY) and GAAP EPS of $0.46, beating…
The raised guidance and strong Q3 beat, combined with FDA IDE approvals for ENHANCE Heart Part B and DENOVO Lung trials, signal accelerating commercial momentum and a clear pipeline catalyst path…
- BULLISH INST-CLUSTERJun 12, 2026
TransMedics attracted heavy net institutional accumulation in Q3 2024, with 25 buyers adding…
The divergence between active asset-manager accumulation and quant-fund exit is a high-conviction structural signal: active managers are betting on fundamental execution of the OCS commercial…
All TMDX filing & press-release reports (9)
- 144 reportNov 9, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportNov 5, 2026
- INST-CLUSTER reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- DEFA14A reportApr 10, 2026
- CLUSTER reportMar 2, 2026
- 8-K reportFeb 27, 2026
- 8-K reportFeb 24, 2026